SCHEMBL9698792

SCHEMBL9698792

O=C(O)CN1C(=O)CNc2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.57
BRPF1 P55201 1/20 0.53
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 1/20 0.46
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45
CA12 O43570 1/20 0.45
CA9 Q16790 1/20 0.45
HSD17B3 P37058 1/20 0.42
EDNRB P24530 1/20 0.40
EDNRA P25101 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
OGFRL1 Q5TC84 1/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5025475 0.85 MEN1 (0.53) TSHRBRPF1MEN1KMT2AALDH1A1
SCHEMBL16190011 0.80 TSHR (0.55) TSHRMEN1KMT2A
SCHEMBL10285253 0.76 BRPF1 (0.54) BRPF1MEN1KMT2AALDH1A1GSK3A
SCHEMBL11455051 0.76 BRPF1 (0.63) TSHRBRPF1ALDH1A1GSK3AGSK3B
SCHEMBL8893469 0.76 CA12 (0.40) MEN1KMT2ACA12CA9
SCHEMBL7818846 0.76 BRPF1 (0.57) TSHRBRPF1MEN1KMT2AALDH1A1
SCHEMBL11500353 0.75 GAA (0.54) TSHRBRPF1MEN1KMT2AALDH1A1
SCHEMBL4597653 0.74 TSHR (1.00) TSHRMEN1KMT2AALDH1A1GSK3A
SCHEMBL8793695 0.73 KMT2A (0.42) BRPF1MEN1KMT2AALDH1A1CA12
SCHEMBL31285850 0.73 KMT2A (0.42) BRPF1MEN1KMT2AALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357307-A1 CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING ILLUMINA, INC. 2023-11-09 US disclosed
US-20230357307-A1 CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING ILLUMINA, INC. 2023-11-09 US disclosed
WO-1992005160-A1 4-ARYLSULFONYL-3,4-DIHYDRO-2(1H)-QUINOXALINONE-1-ALKANOIC ACIDS, ESTERS, AND SALTS SARGES REINHARD (US) 1992-04-02 WO disclosed
US-4940708-A 4-arylsulfonyl-3,4-dihydro-2(1H)-quinoxalinone-1-alkanoic acids, esters, and salts PFIZER INC. (US) 1990-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357307-A1 CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING TENT4A, TENT4B, DNTT TSHR 3314/4885BRPF1 2825/4885MEN1 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.